Respiratory Syncytial Virus (Prevention)

Efficacy of Vaccine Reaffirmed after First Season's Use

Published in TB and Outbreaks Week, November 15th, 1999

MedImmune, Inc. announced that additional safety and efficacy data on the use of Synagis (palivizumab) for the prevention of serious respiratory syncytial virus (RSV) disease in pediatric patients at high risk for RSV disease was presented at the Second World Congress of Pediatric Infectious Diseases in Manila, Philippines, November 2-6, 1999.

Data presented included the clinical outcomes of patients receiving Synagis during the 1998/1999 RSV season, the drug's first season of general use in the United States. Also presented were data from an Expanded Access Study in 15 countries where Synagis was not yet available during the 1998/1999 season.

All...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1999-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry